Glatiramer Acetate Injection, Solution
Product Images NDC 0378-6961

16 FDA label images from Mylan Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Glatiramer Acetate (NDC 0378-6961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Glatiramer Acetate Structural Formula (5cd25695 8a5c 48b6 Bd73 86a48de41493 01)

Glatiramer Acetate Structural Formula (5cd25695 8a5c 48b6 Bd73 86a48de41493 01)
Chemical structure of Glatiramer (Glatiramer Acetate) shown as a formula with amino acid residues including Glu, Ala, Lys, and Tyr, representing its polymeric composition.*
FDA Label Image

Figure 1: Time To Second Exacerbation (5cd25695 8a5c 48b6 Bd73 86a48de41493 02)

Figure 1: Time To Second Exacerbation (5cd25695 8a5c 48b6 Bd73 86a48de41493 02)
A Kaplan-Meier curve comparing the percentage of patients experiencing second exacerbation over time between Glatiramer Acetate 40 mg/mL injection and placebo groups. The graph shows cumulative incidence on the y-axis over approximately 1080 days on the x-axis, with Glatiramer Acetate having a lower rate of second exacerbations compared to placebo.*
FDA Label Image

Figure 2: Median Cumulative Number Of Gd-enhancing Lesions (5cd25695 8a5c 48b6 Bd73 86a48de41493 03)

Figure 2: Median Cumulative Number Of Gd-enhancing Lesions (5cd25695 8a5c 48b6 Bd73 86a48de41493 03)
A line chart comparing the median cumulative number of enhancing lesions over 9 months between Glatiramer Acetate and placebo groups. The x-axis represents months from 0 to 9, and the y-axis shows the median cumulative number of enhancing lesions, with Glatiramer Acetate consistently showing fewer lesions than placebo over time.*
FDA Label Image

Instructions For Use Figure A (Image 14)

Instructions For Use Figure A (Image 14)
An instructional illustration showing components used with Glatiramer Acetate injection. It includes a sharps disposal container, syringe in blister package, injection diary, cotton balls, and alcohol wipes, all arranged and labeled to assist with subcutaneous injection management.*
FDA Label Image

Instructions For Use Figure B (Image 15)

Instructions For Use Figure B (Image 15)
An instructional illustration showing two hands preparing a product by peeling or removing a cover or protective strip from a narrow, elongated item, possibly a medicinal applicator or swab. The image demonstrates the correct manual handling step.*
FDA Label Image

Instructions For Use Figure C (Image 16)

Instructions For Use Figure C (Image 16)
Injection site diagram for Glatiramer Acetate solution, subcutaneous. Illustrations highlight recommended injection areas including abdomen (avoiding 2 inches around belly button), back of hips and arms (fleshy areas below waist and upper back of arms), arms (upper back portion), and thighs (2 inches above the knee and 2 inches below the groin).*
FDA Label Image

Instructions For Use Figure D (Image 17)

Instructions For Use Figure D (Image 17)
An instructional illustration labeled Figure D showing a hand pulling a piece of adhesive tape or similar material away from a surface, demonstrating a removal or preparation step, likely related to proper administration or site preparation for injection.*
FDA Label Image

Instructions For Use Figure E (Image 18)

Instructions For Use Figure E (Image 18)
Illustration showing step-by-step instructions for handling a syringe. The images depict a hand holding a syringe, another hand pulling a cap off the needle, and finally the syringe with the cap removed, likely demonstrating preparation for injection.*
FDA Label Image

Instructions For Use Figure F (Image 19)

Instructions For Use Figure F (Image 19)
An instructional illustration labeled 'Figure F' showing a hand pinching the skin on an arm, demonstrating how to prepare the injection site for a subcutaneous injection.*
FDA Label Image

Instructions For Use Figure G (Image 20)

Instructions For Use Figure G (Image 20)
An instructional illustration labeled Figure G showing the proper technique for administering a subcutaneous injection. It depicts a hand holding a syringe at an angle, injecting into the skin of the opposite arm.*
FDA Label Image

Instructions For Use Figure H (Image 21)

Instructions For Use Figure H (Image 21)
Illustration showing a person injecting a subcutaneous injection into the abdomen. The illustration focuses on the correct positioning and technique for administering an injection, with one hand holding the syringe and the other hand pinching the skin at the injection site.*
FDA Label Image

Instructions For Use Figure I (Image 22)

Instructions For Use Figure I (Image 22)
An instructional illustration showing a hand administering a subcutaneous injection using a syringe into the skin, depicting the correct injection technique for Glatiramer Acetate injection, solution.*
FDA Label Image

Instructions For Use Figure J (Image 23)

Instructions For Use Figure J (Image 23)
Illustration showing a hand holding a syringe, injecting a subcutaneous injection into the skin near the upper arm or shoulder area. The image demonstrates the proper technique for administering a subcutaneous injection, relevant to Glatiramer Acetate injection.*
FDA Label Image

Instructions For Use Figure K (Image 24)

Instructions For Use Figure K (Image 24)
An instructional illustration labeled Figure K depicts a person administering a subcutaneous injection into the abdomen, showing the arm pulling the skin taut to prepare for injection.*
FDA Label Image

Instructions For Use Figure L (Image 25)

Instructions For Use Figure L (Image 25)
An illustration of a medical sharps disposal container with a biohazard symbol on the front. The container has a lid for secure disposal of needles or syringes, commonly used for safe disposal of injection-related waste.*
FDA Label Image

Glatiramer Acetate Injection 40 mg/ml Carton Label (Image 01)

Glatiramer Acetate Injection 40 mg/ml Carton Label (Image 01)
An instructional diagram illustrating components used for subcutaneous injection of Glatiramer Acetate 40 mg/mL. It shows a sharps disposal container, syringe in a blister package, cotton balls, alcohol wipes, and an injection diary used to track doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.